title: Ki-ras activation in vitro affects G1 and G2M cell-cycle transit times and apoptosis.
abstract: Mutant ras genes occur frequently in human neoplasia and, in particular, in pancreatic, colorectal, and lung adenocarcinomas. Recent evidence suggests that G-->T and G-->C transversions of the Ki-ras gene in codon 12 may lead to biological effects in vitro and in vivo that may be associated with an abnormal cell cycle and increased tumour aggressiveness. The role of Ki-ras activation (a G-->C transversion in codon 12, arginine for glycine) in the cell cycle and apoptosis was investigated using control and permanently transfected NIH3T3 mouse fibroblasts. Flow cytometry was used to evaluate the G1-, S- and G2M-phase transit times, the potential doubling time, the growth fraction, and the cell loss factor during asynchronous exponential growth. Apoptosis was induced in both cell lines by absence of growth factors for an extended period of time (72 h) and quantitatively evaluated using the TUNEL method coupled with flow cytometry. It was found that codon 12 G-->C Ki-ras transfected cells compared with controls, had a significant prolongation of G1 by about 50%, a reduction of the G2M transit time by 30%, and a decrease of the cell loss factor by about 90%. Apoptotic cells were about 10% in control and less than 0.5% in Ki-ras transfected cells after 72 h starvation-confluency. These data suggest that codon 12 G-->C Ki-ras activation in mouse NIH3T3 fibroblasts is associated with deregulation of checkpoint controls in the G1 and G2M phases of the cell cycle and inhibition of apoptosis. It appears plausible that these cell mechanisms are related to a proliferative advantage and that they may also be important in the progression of human tumours characterized by specific Ki-ras mutations.
authors.affiliation: Laboratory of Biophysics and Cytometry, National Cancer Institute (I. S.T.), Genoa, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Orecchia
authors.forename: E
authors.initials: E
authors.lastname: Infusini
authors.forename: A
authors.initials: A
authors.lastname: Sciutto
authors.forename: A
authors.initials: A
authors.lastname: Rapallo
authors.forename: A
authors.initials: A
authors.lastname: Di Vinci
authors.forename: S
authors.initials: S
authors.lastname: Nigro
authors.forename: E
authors.initials: E
authors.lastname: Geido
authors.forename: W
authors.initials: W
authors.lastname: Giaretti
mesh_terms: D016475:3T3 Cells; D000818:Animals; D017209:Apoptosis / Q000235:genetics*; D015342:DNA Probes; D005434:Flow Cytometry; D005786:Gene Expression Regulation / Q000235:genetics*; D011905:Genes, ras / Q000235:genetics*; D006801:Humans; D020287:In Situ Nick-End Labeling; D007399:Interphase / Q000235:genetics*; D008677:Metaphase / Q000235:genetics; D051379:Mice; D009363:Neoplasm Proteins / Q000378:metabolism*; D016283:Proto-Oncogene Proteins p21(ras) / Q000378:metabolism*; D014162:Transfection
chemical_list: D015342:DNA Probes; D009363:Neoplasm Proteins; C501009:HRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras)